Tag Archives: Warren Woessner

BIO’s Modest Proposal – Eliminate Rule 56

Posted on December 7, 2011 by Warren Woessner

BIO recently sent Director Kappos 13 pages of comments on the PTO’s proposed revisions to 37 C.F.R. §1.56(b). (A copy of the comments is available at the end of this post.) BIO clearly is struggling to reconcile the differing views … Continue reading →

Posted in Inequitable Conduct/Rule 56 | Tagged AIA, bio, biotechnology law, biotechnology news, Federal Circuit, intellectual property, ip, IP law tools, Patent Law, patents, Rule 56, Therasense, USPTO, Warren Woessner | Leave a comment

Biotech IP Newsletters

Posted on December 6, 2011 by Warren Woessner

Find below biotech IP newsletters recently provided by Dr. Stefan Danner. SPCs For Combination Products – Opinion Of The Advocate General EPO Ruling On The Patentability Of Medical Treatments By Therapy

Posted in Non-U.S. Practice | Tagged Dr. Stefan Danner, EPO, intellectual property, Patent Law, Warren Woessner | Leave a comment

HUMAN GENOME SCIENCES v. ELI LILLY – Increased European Harmony?

Posted on December 2, 2011 by Warren Woessner

By Paul Cole, European Patent Attorney, Lucas & Co – Warlingham, UK Judgement – Human Genome Sciences Inc (Appellant) v Eli Lilly and Company (Respondent) The above proceedings relate to European Patent (UK) 0,939,804 concerning a new human protein called Neutrokine-α. … Continue reading →

Posted in EP and UK Practice | Tagged court of appeals, Eli Lilly, EPO, Patent Law, Paul Cole, Supreme Court, Warren Woessner | 1 Comment

Prometheus’s Brief – Don’t Confuse Us With “LabCorp”

Posted on November 21, 2011 by Warren Woessner

It took me a while to get around to reading Prometheus’s brief to the Supreme Court in Mayo v. Prometheus Labs., No. 10-1150 (S. Ct. Oct. 31, 2011), because I was pretty sure how it would read and, in fact, … Continue reading →